
Advances in Cancer Research
Description
Key Features
- Provides information on cancer research
- Offers outstanding and original reviews on a range of cancer research topics
- Serves as an indispensable reference for researchers and students alike
Readership
Researchers and students in the basic and clinical sciences of cancer biology and oncology, plus related areas in genetics, immunology, pharmacology, cell biology, and molecular biology
Table of Contents
1. Leveraging Epigenetics to Enhance the Cellular Response to Chemotherapies and Improve Tumor Immunogenicity
Liliya Tyutyunyk-Massey, Syed Haqqani, Reshma Mandava, Kirubel Kentiba, Mallika Dammalapati, Nga Dao, Joshua Haueis, David Gewirtz and Joseph W. Landry
2. VDAC Regulation: A Mitochondrial Target to Stop Cell Proliferation
Diana Fang and Eduardo N. Maldonado
3. Acquired Resistance to Drugs Targeting Tyrosine Kinases
Steven A. Rosenzweig
4. Extracellular Regulated Kinases: Signaling From Ras to ERK Substrates to Control Biological Outcomes
Scott T. Eblen
5. Role of MDA-7/IL-24 a Multifunction Protein in Human Diseases
Mitchell E. Menezes, Praveen Bhoopathi, Anjan K. Pradhan, Luni Emdad, Swadesh K. Das, Chunqing Guo, Xiang-Yang Wang, Devanand Sarkar and Paul B. Fisher
6. Advances and Challenges of HDAC Inhibitors in Cancer Therapeutics
Jesse J. McClure, Xiaoyang Li and C. James Chou
7. Prospects of Gene Therapy to Treat Melanoma
Mitchell E. Menezes, Sarmistha Talukdar, Stephen L. Wechman, Swadesh K. Das, Luni Emdad, Devanand Sarkar and Paul B. Fisher
Product details
- No. of pages: 248
- Language: English
- Copyright: © Academic Press 2018
- Published: March 15, 2018
- Imprint: Academic Press
- eBook ISBN: 9780128151280
- Hardcover ISBN: 9780128151273
About the Serial Volume Editors
Kenneth Tew

The Tew laboratory maintains an interest in using redox pathways as a platform to develop therapeutic strategies through drug discovery/development and biomarker identification. We interrogate how reactive oxygen and nitrogen species (ROS/RNS) impact cancer cells and develop novel drugs that impact on glutathione based pathways. Our research efforts have been integral to studies that have identified glutathione S-transferases (GST) as important in drug resistance, catalytic detoxification and as arbiters of kinase-mediated cell signaling events. In addition, we have been instrumental in defining how GSTP contributes to the process by which cells respond to ROS by selective addition of glutathione to specific protein clusters, so called S-glutathionylation. Each of these research areas has had broad impact on a number of cancer disciplines. Moreover, we have also been seminally involved in the Phase I to III clinical testing of three oncology drugs, Telcyta, Telintra and NOV-002. Other ongoing translational efforts have produced two ongoing clinical trials to measure the effectiveness of serum S-glutathionylated serine proteinase inhibitors as possible biomarkers for exposure to hydrogen peroxide mouthwashes and radiation.
Affiliations and Expertise
Paul Fisher
